Group 1 - The core viewpoint is that Boji Pharmaceutical (300404) is one of the few CRO companies capable of providing integrated services for traditional Chinese medicine (TCM) research and development [1] - The company's TCM business has experienced rapid growth in recent years, with steady increases in service projects, orders, and revenue [1] - The increasing emphasis from the government on the TCM industry is expected to create new development opportunities for the sector [1]

Core Viewpoint - WuXi AppTec (药明康德) has reported its best-ever half-year performance for 2025, with significant revenue and profit growth driven by investment gains and reduced expenses [2][3][4]. Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.799 billion yuan, a year-on-year increase of 20.64% [4][5]. - The net profit attributable to shareholders reached 8.561 billion yuan, marking a year-on-year growth of 101.92%, the first time the company has doubled its net profit in the first half since its A-share listing [4][9]. - Investment income for the first half of 2025 was 3.669 billion yuan, significantly up from 22 million yuan in the same period last year, primarily due to the sale of shares in an associate company [9]. Cost Management - WuXi AppTec has successfully reduced management and R&D expenses in the first half of 2025, with management expenses at 1.175 billion yuan and R&D expenses at 514 million yuan, both showing a decrease compared to the previous year [3][10]. - Sales expenses were 394 million yuan, accounting for 1.89% of revenue, down from 2.08% in the previous year [10]. Business Segments - The chemical business generated 16.3 billion yuan in revenue, a 33.5% increase year-on-year, while the small molecule drug discovery business contributed 8.68 billion yuan, up 17.5% [6]. - The TIDES business saw remarkable growth, with revenue reaching 5.03 billion yuan, a 141.6% increase [6]. - The testing business generated 2.69 billion yuan, with laboratory analysis and testing contributing 1.89 billion yuan, a slight increase of 0.4% [6]. Regional Performance - Revenue from U.S. clients was 14.03 billion yuan, up 38.4%, while European clients contributed 2.33 billion yuan, a 9.2% increase. Revenue from Chinese clients decreased by 5.2% to 3.15 billion yuan [7]. Future Outlook - WuXi AppTec has raised its full-year revenue guidance for 2025, expecting a growth rate of 13% to 17%, up from the previous estimate of 10% to 15% [7]. - The company reported a backlog of 56.69 billion yuan in ongoing business, a 37.2% increase year-on-year, indicating strong future demand [8]. Market Reaction - Following the impressive half-year results, WuXi AppTec's A-shares rose by 7.72% and H-shares increased by 11.25% on July 28 [12].

Core Viewpoint - WuXi AppTec, a leading CRO company, reported strong financial performance for the first half of 2025, with significant revenue and profit growth, and announced its first interim dividend to share growth benefits with global investors [1][2][3]. Financial Performance - The company achieved a revenue of 20.799 billion yuan in the first half of 2025, representing a year-on-year increase of 20.64% [1][2]. - Net profit attributable to shareholders reached 8.56 billion yuan, marking a substantial year-on-year growth of 101.92% [1][2]. - Adjusted Non-IFRS net profit was 6.31 billion yuan, up 44.4% year-on-year, with a net profit margin reaching a historical high of 30.4% [2][3]. - Operating cash flow was 7.07 billion yuan, a significant increase of 49.1% year-on-year, providing ample resources for capacity expansion and shareholder returns [2][3]. Orders and Growth Drivers - The company reported a record high of 56.69 billion yuan in backlog orders, reflecting a year-on-year growth of 37.2% [2][3]. - The small molecule CDMO pipeline exceeded 3,400 projects, with 412 new additions in the first half of 2025 [2]. - Revenue from TIDES (oligonucleotides and peptides) reached 5.03 billion yuan, showing a remarkable year-on-year growth of 141.6%, becoming a new growth engine for the company [2]. Shareholder Returns - The board approved the first-ever interim dividend of 3.5 yuan per 10 shares, totaling approximately 1 billion yuan [3]. - Cumulative shareholder returns since the beginning of 2025 are approaching 7 billion yuan, including completed dividends and share buybacks [3]. - The company plans to increase buyback efforts if the stock price remains undervalued, with total shareholder returns expected to reach 8 billion yuan for the year [3]. Revised Guidance - The company raised its full-year guidance for 2025, increasing the revenue growth forecast from 10%-15% to 13%-17%, with total revenue expectations adjusted from 41.5 billion-43 billion yuan to 42.5 billion-43.5 billion yuan [3]. - Free cash flow projections were revised upward from 4 billion-5 billion yuan to 5 billion-6 billion yuan [3]. - Capital expenditures are maintained at 7 billion-8 billion yuan for global capacity and capability building [3]. Institutional Holdings - As of July 28, 2025, 395 institutional investors held shares in WuXi AppTec, with a total holding of 1.159 billion shares, accounting for 40.37% of total shares [4]. - The top ten institutional investors collectively held 32.40% of shares, with an increase of 2.81 percentage points from the previous quarter [4]. - There were 53 public funds that increased their holdings, while 154 public funds reduced their holdings compared to the previous quarter [5].

Core Insights - Wuxi AppTec reported a strong performance in the first half of 2025, with revenue reaching 20.799 billion yuan, a year-on-year increase of 20.64% [1] - The net profit attributable to shareholders was 8.56 billion yuan, reflecting a significant year-on-year growth of 101.92% [1] - The company plans to increase its full-year revenue forecast to between 42.5 billion and 43.5 billion yuan, up from the previous estimate of 41.5 billion to 43 billion yuan [4] Financial Performance - Revenue from continuing operations grew by 24.24% year-on-year [1] - Adjusted net profit (non-IFRS) for the first half of 2025 increased by 44.4% [5] - The company achieved a record high of 56.7 billion yuan in backlog orders for continuing operations [5] Shareholder Returns - Wuxi AppTec announced a special dividend of approximately 1 billion yuan, which has already been completed [5] - The board approved a mid-year profit distribution plan, proposing a total cash dividend of around 1 billion yuan [5] - The company has executed multiple share repurchase plans totaling 4 billion yuan since 2024, with the latest repurchase amounting to 1 billion yuan [6][8] Future Outlook - The company expects its continuing operations revenue growth to return to double digits, with an adjusted growth rate of 13-17% [4] - Capital expenditures for 2025 are projected to reach 7-8 billion yuan, with free cash flow expectations adjusted to 5-6 billion yuan [5]

Core Viewpoint - The FDA has updated its policy to gradually eliminate mandatory animal testing for monoclonal antibody therapies and other drug developments, which has raised significant concerns in the industry, particularly for companies like Zhaoyan New Drug that rely heavily on animal testing [1][2]. Group 1: FDA Policy Changes - The FDA's new policy encourages the use of alternative methods such as computational models, organ-on-a-chip technology, and cross-species data integration to replace animal testing [1][4]. - The FDA's push for alternatives is seen as a potential milestone in drug development, which could impact not only domestic CRO companies but also global pharmaceutical research [4][5]. Group 2: Impact on Zhaoyan New Drug - Zhaoyan New Drug, which derives 95% of its revenue from non-clinical research, faces direct challenges as approximately 70% of its business involves animal testing [10][11]. - The company has a significant portion of its business (78%) from the domestic market, with only 22% from international markets, primarily the U.S. [10][11]. Group 3: Feasibility of Alternatives - The feasibility of AI and organ-on-a-chip technologies as alternatives to animal testing is being explored, with some advancements already noted in clinical trials [5][7]. - The FDA has previously approved a new drug based solely on organ-on-a-chip data, indicating that there is a pathway for these technologies to be integrated into drug development [7]. Group 4: Financial Implications - If animal testing is reduced, the cost of monkeys used in experiments may decline significantly, impacting Zhaoyan New Drug's investments in animal resources [14]. - The company's financial growth may increasingly depend on its clinical business, which is facing intense competition and declining profit margins [15].

股票简称：万邦医药 股票代码：301520 安徽万邦医药科技股份有限公司 Anhui Wanbang Pharmaceutical Technology Co.,Ltd. （安徽省合肥市高新区明珠大道与火龙地路交口西南角安徽万邦医药 1 号楼） 二零二三年九月 特别提示 安徽万邦医药科技股份有限公司（以下简称"万邦医药"、"本公司"或"发 行人"、"公司"）股票将于 2023 年 9 月 25 日在深圳证券交易所创业板上市， 该市场具有较高的投资风险。创业板公司具有业绩不稳定、经营风险高、退市风 险大等特点，投资者面临较大的市场风险。投资者应充分了解创业板市场的投资 风险及本公司所披露的风险因素，审慎做出投资决定。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在创业板上市招股说明书中的相同。 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （中国（上海）自由贸易试验区浦明路 8 号） 1 | | | | 特别提示 | 1 | | -- ...